Amarin makes IEX debut

AMARIN Corporation, the international pharmaceutical company, debuted on the IEX Exchange — the Irish Stock Exchange’s market for small and medium-sized companies — yesterday.

The company specialises in the research, development and commercialisation of drugs for central nervous system disorders and started life as an offshoot of Elan.

Amarin began trading in Dublin, yesterday, at a price of €2.02 — a starting point largely influenced by its current trading levels on the Nasdaq. The company, which has also listed on London’s Alternative Investment Market (AIM), is the first firm with a primary listing on the Nasdaq to seek an additional listing on the IEX. It also brings to 18 the number of companies listed on the IEX since its inception in April last year.